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In the recent years, it has been demonstrated that the biological activity of mesenchymal
stem cells (MSCs) is mediated through the release of paracrine factors. Many of these
factors are released into exosomes, which are small membranous vesicles that participate
in cell–cell communication. Exosomes from MSCs are thought to have similar functions to
MSCs such as repairing and regeneration of damaged tissue, but little is known about the
immunomodulatory effect of these vesicles. Based on an extensive bibliography where
the immunomodulatory capacity of MSCs has been demonstrated, here we hypothesized
that released exosomes from MSCs may have an immunomodulatory role on the dif-
ferentiation, activation and function of different lymphocyte subsets. According to this
hypothesis, in vitro experiments were performed to characterize the immunomodulatory
effect of human adipose MSCs derived exosomes (exo-hASCs) on in vitro stimulated T cells.
The phenotypic characterization of cytotoxic and helperT cells (activation and differentiation
markers) together with functional assays (proliferation and IFN-γ production) demonstrated
that exo-hASCs exerted an inhibitory effect in the differentiation and activation of T cells
as well as a reduced T cell proliferation and IFN-γ release on in vitro stimulated cells. In
summary, here we demonstrate that MSCs-derived exosomes are a cell-derived product
that could be considered as a therapeutic agent for the treatment of inflammation-related
diseases.
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INTRODUCTION
Exosomes are small membranous vesicles secreted by most cell
types. These vesicles participate in cell–cell communication and
their content consists of RNA, lipids, and proteins. Some of these
proteins (i.e., CD9, CD63, or CD81) are ubiquitously expressed,
but depending on the cell source, cell type-specific proteins can
be found being responsible of their functionality. The proteins,
lipids, and RNA expression of exosomes from different cells and
organisms are extensively described in ExoCarta database (1).
Exosomes can be easily isolated by ultracentrifugation from
in vitro cultured cells but different isolation protocols have been
described in the literature (2). All these protocols differ from each
other on the basis of particular types of research being divided as
procedures for discovery, diagnostic, or preparative research (3).
For a clinical-grade production of exosomes, safe technologies for
large scale production are an absolute prerequisite (4).
In preclinical settings, especially in murine models, exosomes
have been applied for the treatment of many different diseases such
as infections (5, 6), allergies (7) as well as autoimmune diseases (8,
9). Regarding the immunomodulatory potential of these vesicles,
the first in vivo studies were conducted by Pêche et al. using bone
marrow dendritic cell-derived exosomes (10, 11). Compared to
preclinical studies, only a few clinical trials have been conducted
using exosomes. Some of the first clinical trials were conducted
in cancer patients using dendritic cell-derived exosomes (12) and
ascites-derived exosomes (13) where the safety, tolerability, and
efficacy of the treatments were demonstrated.
At the present, the therapeutic potential of exosomes derived
from MSCs (Exo-MSCs) has been successfully applied in murine
models for the treatment of cardiovascular diseases (14). In this
sense, the proangiogenic effect described in different stem cell
subsets may be the responsible of this therapeutic effect (15).
There are no differences in terms of morphological features,
isolation, and storage conditions between exosomes derived from
MSCs and other sources. As to the identification, exo-MSCs
express not only the common surface markers of exosomes, such
as CD9 and CD81, but also some adhesion molecules, including
CD29, CD44, and CD73, which are expressed on the membrane
of MSCs (16).
Accumulative evidences have established that, the effect of
MSC transplantation is thought to be mediated in part, by a
paracrine effect. Indeed, in the context of myocardial infarct it
was experimentally quantified that the overall beneficial effect
of paracrine mechanisms accounted between 50 and 80% (17).
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Several advantages of using released factors from MSCs have been
described. For example, transferred cells may die or not fully home
into the site of damaged tissue whereas biological factors can be
locally administered with a controlled dosage (18).
Current preclinical trials with exo-MSCs have been driven for
repairing damaged tissues, but few reports have been focused on
the immunomodulatory effect of these vesicles. Here, we hypoth-
esize that exo-MSCs may have similar regulatory functions than
the original MSCs source on the differentiation, activation and
function of different T cell subsets (16).
Supporting this idea, previous reports have demonstrated that
the immunomodulatory capacity of MSCs against NK cells (19,
20), cytotoxic T lymphocytes (21), γδ T cells (22), dendritic cells
(23, 24), or invariant NKT cells (25) is mediated by a paracrine
mechanism.
In order to address this hypothesis, in vitro experiments were
performed to characterize the immunomodulatory effect of exo-
MSCs on in vitro stimulated T cells. The phenotypic characteriza-
tion of cytotoxic and helper T cells (activation and differentiation
markers) together with functional assays (proliferation and IFN-γ
production) demonstrated that exo-MSCs exerted an inhibitory
effect in the differentiation and activation of T cells as well as
a reduced proliferation and IFN-γ release on in vitro expanded
T cells. In summary, our results suggest that, exo-MSCs are a
cell-derived product that could be considered as an immunomod-
ulatory therapeutic agent for the treatment of immunological
diseases.
MATERIALS AND METHODS
HUMAN ADIPOSE MESENCHYMAL STEM CELLS ISOLATION AND
EXPANSION
The human adipose mesenchymal stem cells (hASCs) were iso-
lated from lipoaspirates obtained from human adipose tissue from
healthy adult donors. Lipoaspirates were washed with PBS, and
digested with collagenase type I in PBS. The digested sample was
washed with 10% of fetal bovine serum (FBS), treated with ammo-
nium chloride 160 mM, suspended in culture medium (DMEM
containing 10% FBS), and filtered through a 40µm nylon mesh.
Cells were seeded onto tissue culture flasks and expanded at 37°C
and 5% CO2, changing the culture medium every 7 days. Cells
were passed to a new culture flask when cultures reached 90%
of confluence. In addition, hASCs were tested by flow cytometry
using specific surface markers being negative for CD14, CD31,
CD34, CD45 and positive for CD29, CD59, CD90, and CD105
(data not shown). Cell lines from two healthy donors were used
in the study. The biological samples were obtained after informed
consent under the auspices of the appropriate Research and Ethics
Committees.
ISOLATION AND PURIFICATION OF EXOSOMES FROM hASCs
An enriched fraction of exosomes from hASCs (exo-hASCs) was
obtained from hASCs cultured in 175 cm2 flasks. When cells
reached a confluence of 80%, culture medium (DMEM contain-
ing 10% FBS) was replaced by exosome isolation medium (DMEM
containing 1% insulin–transferrin–selenium). The hASCs super-
natants were collected every 3–4 days. Exosomes were isolated
from supernatants by two successive centrifugations at 1000× g
(10 min) and 5000× g (20 min) at 4°C to eliminate cells and
debris, followed by an ultracentrifugation at 100,000× g for 6 h
to precipitate exosomes. The pellets were resuspended in 250µL
of PBS and stored at −20°C. Prior to in vitro experiments, exo-
somes were quantified by Bradford assays and characterized by
nanoparticle tracking analysis.
CHARACTERIZATION OF exo-hASCs
The concentration and size of purified exosomes were mea-
sured by nanoparticle tracking analysis (NanoSight Ltd,Amesbury,
UK) that relates the rate of Brownian motion to particle size.
Results were analyzed using the nanoparticle tracking analysis soft-
ware package version 2.2. Triplicate samples were diluted 1:10 in
sterile-filtered PBS and analyzed.
BRADFORD ASSAY
Exosome concentrations were indirectly measured by protein
quantification in a Bradford assay. To quantify protein concen-
tration, 20µL of exosomes sample were incubated with 180µL
of Bradford reagent (Bio Rad Laboratories, Hercules, CA) at RT.
Absorbance was read 5 min after at 595 nm, and protein concen-
tration was extrapolated from a standard concentration curve of
Bovine Serum Albumin.
LYMPHOCYTES ISOLATION AND PRESERVATION
Peripheral blood lymphocytes (PBLs) from healthy donors were
obtained by centrifugation over Histopaque-1077 (Sigma, St.
Louis, MO, USA) and washed twice with PBS. The PBLs were
frozen and stored in liquid nitrogen. For in vitro experiments,
cell aliquots were thawed at 37°C, added to 10 mL of RPMI
1640 and centrifuged at 1500 rpm for 5 min to eliminate DMSO.
Pellet was resuspended in RPMI 1640 supplemented with 10%
of FBS.
IN VITRO STIMULATION OF T CELLS AND CO-CULTURE WITH
EXOSOMES
To determine the immunomodulatory effect of exo-hASCs on
in vitro stimulated PBLs, 2× 105 purified PBLs were seeded in
a 96 wells plate (200µl per well). To stimulate PBLs, a T cell acti-
vation/expansion kit (Miltenyi Biotec Inc, San Diego, CA, USA)
was used, adding 5µL of microbeads coated with anti-CD2/anti-
CD3/anti-CD28 to each well. Finally, exosomes at different con-
centrations (4, 8, and 16µg/106 PBLs) were added to wells. The
PBLs were cultured for 6 days. Negative controls (non-stimulated
PBLs) and positive controls (stimulated PBLs without exosomes)
were used in all the experiments.
CFSE PROLIFERATION ASSAY
The proliferative behavior of T cells was quantified by carboxy-
fluorescein succinimidyl ester (CFSE) dilution. The CFSE staining
was performed before seeding, using the CFSE cell proliferation
kit (Invitrogen, Eugene, OR) at a final concentration of 10µM for
10 min at 37°C, followed by immediate quenching with culture
medium. After 6 days, in vitro stimulated PBLs in the presence
or absence of exo-hASCs were tested for CFSE dilution by flow
cytometry.
Frontiers in Immunology | Immunotherapies and Vaccines November 2014 | Volume 5 | Article 556 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blazquez et al. Immunomodulatory potential of exo-hASCs on T cells
DIFFERENTIATION/ACTIVATION MARKERS EXPRESSION ANALYSIS ON
IN VITRO STIMULATED PBLs
For flow cytometric analysis of in vitro stimulated PBLs, the cells
were collected from wells after 6 days by pipetting up and down.
The cells were stained with fluorescence-labeled human mono-
clonal antibodies against CD3 (SK7), CD4 (SK3), CD8 (SK1),
CCR7 (3D12), CD45RA (L48) (BD Biosciences, San Jose, CA,
USA). The markers expression analysis was performed as follows:
2× 105 cells were incubated for 30 min at 4°C with appropri-
ate concentrations of monoclonal antibodies in the presence of
PBS containing 2% FBS. The cells were washed and resuspended
in PBS. The flow cytometric analysis was performed on a FAC-
Scalibur cytometer (BD Biosciences, San Jose, CA, USA) after
acquisition of 105 events. Cells were primarily selected using for-
ward and side scatter characteristics and fluorescence was analyzed
using CellQuest software (BD Biosciences, San Jose, CA, USA).
Isotype-matched negative control antibodies were used in all the
experiments. The mean relative fluorescence intensity was calcu-
lated by dividing the mean fluorescent intensity (MFI) by the MFI
of its negative control.
INTRACELLULAR GAMMA-INTERFERON ASSAY
For IFN-γ assays, the PBLs were in vitro stimulated with the
T cell activation/expansion kit (Miltenyi Biotec Inc, San Diego,
CA, USA) for 6 days in the presence of exo-hASCs at 16µg/106
PBLs. The PBLs were then incubated for 6 h with BD Gol-
giStop. PBLs were stained with PerCP-labeled anti-CD4 (SK3) and
APC-labeled anti-CD8 (SK1), fixed and permeabilized using BD
Cytofix/Cytoperm fixation/permeabilization kit. Finally, cells were
stained with PE-labeled anti-IFN-γ antibody (all reagents from BD
Biosciences, San Jose, CA, USA). Analysis by flow cytometry was
performed by measuring the frequency of IFN-γ expression on
gated CD3+CD4+ and CD3+CD8+ cells.
STATISTICAL ANALYSIS
Data were statistically analyzed using the Student’s t -test for vari-
ables with parametric distribution. For the proliferation assay, an
ANOVA with post hoc Bonferroni test was performed. The p-values
≤0.10 or≤0.05 were considered statistically significant. All the sta-
tistical determinations were made using SPSS-21 software (SPSS,
Chicago, IL, USA).
RESULTS
SIZE DISTRIBUTION AND CONCENTRATION OF exo-hASCs
An enriched fraction of exosomes was collected from hASCs by
ultracentrifugation. The protein concentration of exosomes was
determined by Bradford assay. Three independently performed
nanoparticle tracking analysis were performed for each exosome
sample to quantify size distribution and particle concentration.
Firstly, the total protein concentration allowed us to quantify
exosomes for in vitro assays. Secondly, the nanoparticle track-
ing analysis allowed us to characterize the released vesicles. The
size of isolated vesicles ranged from 223 to 282 nm and the
mean size and standard deviation was 246.8± 25.05 nm. Rep-
resentative results of exo-hASCs are displayed as a frequency
size distribution graph (Figure 1). The corresponding nanopar-
ticle tracking analysis video frame is included as Video S1
FIGURE 1 | Frequency size distribution graph of exo-hASCs. The
nanoparticle tracking analysis was performed on exosome samples to
quantify size distribution and particle concentration (n=6). A representative
graph of nanoparticle tracking analysis is shown.
in Supplementary Material. Finally, the concentration of exo-
somes (n= 6) was determined by nanoparticle tracking analysis
and ranged between 8.4 and 9.7 (×109) particles per milliliter
and the mean concentration was 9.1± 0.5 (×109) particles per
milliliter.
PROLIFERATIVE ABILITY OF IN VITRO STIMULATED T CELLS
CO-CULTURED IN THE PRESENCE OF exo-hASCs
In order to assess the biological activity of exo-hASCs, we aimed
to determine their effect over the proliferation rate of lym-
phocyte subsets. For that, a total of 2× 106 PBLs were stimu-
lated with anti-CD2/anti-CD3/anti-CD28 as described in Section
“Materials and Methods” and co-cultured with different con-
centrations of exo-hASCs (4, 8, and 16µg/106 PBLs) during
6 days. The proliferation ability was determined by CFSE dilu-
tion. Non-stimulated PBLs were used as negative control, and
stimulated PBLs without exosomes constituted the positive con-
trol. As expected, the proliferation rate of non-stimulated PBLs
was very low (data not shown) and the maximum prolifera-
tion rate was reached by stimulated PBLs without exosomes. A
total of eight cell divisions were detected by CFSE fluorescence.
As shown in the Figure 2A, when in vitro stimulated lympho-
cytes were cultured in the presence of different concentrations
of exo-hASCs, the proliferation rate was proportionally decreased
both in CD4+ and CD8+ T cells. A large percentage of cells pre-
sented a low number of cell divisions, while the highest number
of cell divisions was reached by a lower percentage of cells. A
detailed representation showing the percentage of cells in each
division cycle is provided in the Figure 2A. A representative
histogram (Figure 2B) and a detailed representation showing
the percentage of cells in each division cycle is also provided
(Figure 2C).
Here, it can be seen how increasing concentrations of exo-
somes are arresting both CD4 and CD8 proliferation from eight
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FIGURE 2 |The proliferative ability of in vitro stimulated PBLs is reduced
by exo-hASCs. The PBLs were cultured either alone or co-cultured with
different batches of exo-hASCs (n=8) at different concentrations (4, 8, and
16µg of exosomes per million of PBLs). At day six, PBLs were collected and
T-lymphocytes subsets were stained with anti-CD3, anti-CD4, and anti-CD8.
Fluorescence profiles of CFSE-labeled cells allowed us to identify eight
divisions. A detailed representation of CD4+ T cells and CD8+ T cells showing
the percentage of the total population in each cell division cycle (indicated as
#) is provided (A), as well as a representative histogram (B). The statistical
comparison of lymphocyte subsets at different cell division cycles is also
provided (C). Horizontal bars represent statistically significant differences
between the groups (significant at p≤0.05).
generations to seven. Moreover exosomes are retaining the cells in
the earlier division cycles 4, 5, and 6, in where the percentage of
cells are significantly higher in the presence of exosomes, however,
division cycles 7 and 8 have a significantly reduced percentage of
cells when higher doses of exosomes were used. The first two divi-
sion cycles contain a very low percentage of T cells both in the
presence or absence of exosomes indicating that the effect of the
polyclonal stimulation starts after these two division cycles, nev-
ertheless the presence of exosomes are still significantly retaining
cells in these firs two division cycles (although this is happening
in a group of T cells below 10%). The statistical analysis showed
that, significant differences were found in different division cycles
either in CD4+ and CD8+ T cells. Finally, the stimulation index
was calculated on CD4+ and CD8+ T cells as frequencies of
CFSE-low T cells among unstimulated T cells. The stimulation
index of CD4+ and CD8+ T cells stimulated with anti-CD2/anti-
CD3/anti-CD28 was 692.3 and 655.6, respectively. However, when
PBLs were stimulated in the presence of exosomes, the stain
index significantly decreased on CD4+ T cells (589.93± 39.31,
585± 80.27, 529.14± 58.88 at 4, 8, and 16µg) as well as in CD8+
T cells (519.75± 60.97, 488.03± 107.32, 437.4± 79.25 at 4, 8, and
16µg).
T CELLS SUBSETS DISTRIBUTION OF IN VITRO STIMULATED T CELLS
CO-CULTURED IN THE PRESENCE OF exo-hASCs
The CD45RA isoform and chemokine receptor CCR7 are sur-
face marker commonly used to identify the differentiation stages
of CD4+ and CD8+ T cells. In order to study the effect of exo-
hASCs over lymphocyte subsets, a total of 2× 106 stimulated PBLs
were cultured in the presence of exo-hASCs (from two different
donors) at 16µg/106 PBLs. At day 6, flow cytometry was per-
formed using a commercial antibody against CD45RA and CCR7.
The quantitative expression of CD45RA and CCR7 was normal-
ized referred to control (in vitro stimulated T cells in the absence of
exo-hASCs). Our results showed a significant decrease CD45RA+
and CCR7+ cells both in the CD4+ and CD8+ T cells in the posi-
tive control (stimulated PBLs). However, the loss of CD45RA and
CCR7 on in vitro stimulated PBLs was partially compensated by
the presence of exo-hASCs (Figure 3). Representative histograms
are provided in Figure S1 in Supplementary Material.
In the model proposed by Lanzavecchia and Sallusto, four dif-
ferent stages have been defined within CD8+ T cells according to
the combined analysis of CD45RA and CCR7 expression, namely:
naïve (CD45RA+CCR7+), central memory (CD45RA−CCR7+)
and at least two subset of effector-memory cells: effector-memory
cells (CD45RA−CCR7−) and terminally differentiated effector-
memory cells (CD45RA+CCR7−) (26, 27). To study the effect of
exo-hASCs over this distribution, the co-expression of CD45RA
and CCR7 was analyzed by flow cytometry on CD4+ and CD8+
T cell subsets. As shown in Figure 4, although the percentage
of naïve cells was not significantly modified by the presence
of exo-hASCs, a significant decrease of terminally differenti-
ated effector-memory cells (CD45RA+CCR7−) was observed on
in vitro stimulated CD8+ T cells cultured in the presence of
exo-hASCs. In the case of CD4+ T cells, exo-hASCs reduced
the percentage of effector-memory cells (CD45RA−CCR7−) and
significantly increased the percentage of central memory cells
(CD45RA−CCR7+).
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FIGURE 3 | Percentage of CD45RA and CCR7 expression on in vitro
stimulatedT cells co-cultured in the presence of exo-hASCs. At day 6,
in vitro stimulated PBLs were analyzed for CD45RA and CCR7 on CD8+ and
CD4+ T cell subsets. Two different exo-hASCs at 16µg/106 cells from different
donors were used in these experiments (Exos#1 and Exos#2). The graphs
show the normalized quantitative expression referred to control (in vitro
stimulated T cells in the absence of exo-hASCs). Values shown in the bars
represent mean±SD of three independently performed experiments.
Horizontal bars represent statistically significant differences between the
stimulated PBLs groups (significant at p≤0.1).
FIGURE 4 | CD45RA and CCR7 co-expression on in vitro stimulated
T cells co-cultured in the presence of exo-hASCs. At day 6, in vitro
stimulated PBLs were analyzed for the co-expression of CD45RA and CCR7.
The CD45RA isoform and CCR7 distinguishes four subsets of T cells:
terminally differentiated RA+ T cells (TEMRA, CD45RA+ CCR7−), naïve T cells
(NAIVE, CCR7+ CD45RA+), and two memory subsets: effector memory (EM,
CD45RA− CCR7−) and central memory (CM, CD45RA− CCR7+). Two different
exosomes from different donors were used in these experiments (Exos#1
and Exos#2). Values shown represent mean±SD of 3 independently
performed experiments.
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IFN-γ PRODUCTION ON IN VITRO STIMULATED T CELLS CO-CULTURED
IN THE PRESENCE OF HUMAN ADIPOSE MESENCHYMAL STEM CELLS
DERIVED EXOSOMES
The IFN-γ is a pro-inflammatory cytokine secreted by immune
cells under certain conditions of activation. There is a direct
correlation between IFN-γ secretion and the level of T cell acti-
vation. In order to determine the effect of exosomes on the
secretory IFN-γ response of T cells, PBLs were cultured in the
presence and absence of exo-hASCs during 6 days and intra-
cellular levels of IFN-γ were determined on CD4+ and CD8+
T cell subsets. Our results showed that, at day 6, the per-
centage of intracellular IFN-γ was reduced when PBLs were
cultured with exosomes, in comparison to positive control, in
both T cell subsets. However, this reduction was only statis-
tically significant on gated CD4+ T cells (Figure 5). These
results demonstrated that exo-hASCs impaired not only the
differentiation phenotype of lymphocytes but also their IFN-γ
secretion.
DISCUSSION
The hASCs have been successfully used for the treatment of
numerous diseases (28). These cells can be isolated from the adult
liposuctioned tissue and efficiently expanded in vitro to be used as
an “off-the-shelf” cellular product. At the present, there are quite a
few stem cell products in the market (29) but hASCs are currently
considered one of the most promising cell types for therapeutic
applications that fulfill regulatory requirements.
The hASCs have immunomodulatory properties, which are
directly mediated by cell–cell contact or indirectly mediated
through the release of immunosuppressive factors. The release
of these factors is enhanced under inflammatory conditions
and results in suppression of T cell function (proliferation, dif-
ferentiation, and cytotoxicity) (30), B cell functions (31), NK
cell cytotoxicity (20), decrease in maturation, and activation of
dendritic cells (32) as well as an increase of regulatory T cells (33,
34).
Among the released factors, the exosomes from MSCs have
been considered as a promising candidate for a novel cell-free
therapy. At the present, these microvesicles have been tested in pre-
clinical settings for the treatment of cardiovascular diseases (35),
kidney injury (36), graft-versus-host disease (37), and neurolog-
ical diseases (38). In clinical settings, the exo-MSCs have been
tested in graft-versus-host disease patients, which experienced
improvement in symptoms for 5 months (39).
In these studies, exosomes from MSCs have demonstrated a bio-
logical effect for repairing tissue damage. From an immunological
point of view, these exosomes have demonstrated immunomod-
ulatory properties inducing peripheral tolerance (40) and modu-
lating the immune response (41).
In this work, we aimed to investigate the immunomodulatory
role of an enriched fraction of exo-hASCs on T cell subsets under
in vitro conditions. For this purpose, the T cells were in vitro
expanded and activated with anti-CD2, anti-CD3, and anti-CD28
that partially mimic stimulation by antigen-presenting cells (42).
The immunomodulation was assessed by measuring the prolifer-
ative behavior of T cells, their differentiation toward the memory
lineage and IFN-γ secretory response.
Although this is a preliminary study, our results demonstrated
that exo-hASCs significantly inhibited the proliferation of CD4
and CD8 T cells. These results are very similar to our previously
published results using hASCs co-cultured with in vitro activated
PBLs (30). Recent reports have demonstrated that TNF-α/NF-κB
signaling in MSCs are required for the inhibition of T-cell pro-
liferation (43). In this sense, future studies will be conducted to
evaluate if the anti-proliferative activity of exo-hASCs could also
be related with the activation of NF-κB.
Together with the inhibition of T cell proliferation, here we
hypothesized that exo-hASCs may arrest the T cell differentiation
FIGURE 5 |The exo-hASCs inhibit the IFN-γ production of in vitro
stimulatedT cells. Two different exosomes from different donors
were used in these experiments (Exos#1 and Exos#2). Graphs
represent the mean±SD of 3 independently performed experiments.
A representative dot plot of each condition is represented below each
graph, and numbers in the quadrants indicate the percentage of
IFN-γ in gated CD4+ (A) and CD8+ T cells (B) (significant at
p≤0.05).
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toward effector or memory cell phenotypes. In order to confirm
this hypothesis, in vitro activated lymphocytes were co-cultured
in the presence of exo-hASCs and the differentiation profile
of CD4+ and CD8+ T cells was monitored according to co-
expression of CD45RA and CCR7 molecules. The combined usage
of CD45RA and CCR7 allowed us the identification of different
CD8+ T cell subsets (26) and CD4+ T cell subsets (27): naive
(CCR7+CD45RA+), central memory (CCR7+CD45RA−), effec-
tor memory (CCR7−CD45RA−), and terminally differentiated
effector-memory cells (CD45RA+CCR7−). Our results evidenced
that exo-hASCs hamper the in vitro differentiation mediated by
anti-CD3/CD2/CD28 stimuli. Actually, in the case of CD8+ and
CD4+ T cells, exo-hASCs have an inhibitory effect in the dif-
ferentiation of toward a terminally differentiated phenotype and
effector-memory phenotype, respectively.
These in vitro results with exo-hASCs showed similarities with
previous reports using MSCs and in vitro stimulated PBLs where
the T lymphocytes showed reduced-memory responses after a
tetanus toxoid boost (44). Current experiments are being con-
ducted in a relevant animal model of T cell-mediated disease
(collagen-induced arthritis experimental model for rheumatoid
arthritis). Once completed, these results will give us a more com-
plete understanding of exo-hASCs as a therapeutic agent for the
control of local T cell responses.
Finally, the immunomodulatory activity of exo-hASCs was
determined by measuring IFN-γ production on CD4+ and CD8+
T cells. These experiments confirmed that, similarly to in vitro
experiments using hASCs, both in contact or separated by tran-
swells (30), the IFN-γproduction was significantly reduced by exo-
hASCs. Considering that IFN-γ is crucial for protection against
immune-mediated inflammatory disorders, we could assume that
exo-hASCs could be used as ideal vehicles for a local immunosup-
pression. Moreover, in contrast to cell therapy, where the viability,
homing, or implantation of individual cells is compromised, the
usage of well-characterized exo-hASCs in a dosing regimen that
can be controlled and defined in space and time could be consid-
ered an advantage (45). Additionally, several authors have reported
the susceptibility of allogeneic cells to CD8+ T cells and NK cells,
which is an important issue for the clinical efficacy of MSCs (46).
In the case of exo-hASCs, these microvesicles will not be affected
by cell-mediated lysis, which is an advantage for their therapeutic
effectiveness.
An important aspect to be discussed here is the role of MHC
molecules on exosomes. It has been previously described by Pêche
et al. that, exosomes from bone marrow dendritic cells (exo-
DCs) induce regulatory responses and allograft tolerance through
the presentation of donor-MHC antigens (10). These exo-DCs
are positives for MHC class I, MHC class II, and co-stimulatory
molecules and the in vivo administration of allogeneic exosomes
induced tolerance (11).
Contrary to exo-DCs, the exo-hASCs are characterized by the
absence of MHC class II and co-stimulatory molecules. Regard-
ing to MHC class I, the hASCs cell lines contains very low
levels of MHC class I and the expression of this molecule in
exo-hASCs is still under debate. Indeed, in Exocarta (a database
of exosomal proteins, http://www.exocarta.org/), the presence of
HLA-A, HLA-B, or HLA-C has not been detected in the 939
proteins analyzed from exo-MSCs. However, the proteomic analy-
sis of exosomes from human embryonic stem cell-derived MSCs
have demonstrated the presence of HLA-A molecules in these
vesicles (47).
On the other hand, considering that human clinical trials using
allogeneic hASC is not causing early, aggressive immunological
rejection, we could assume that allogeneic exo-hASCs from non-
activated hASCs might have similar consequences. The absence of
MHC class II and co-stimulatory molecules on exo-hASCs may
also indicate that these vesicles have a direct inhibitory effect on T
cells being independent from antigen presentation. Nevertheless,
although the inhibitory effect was only tested in allogeneic set-
ting (using exo-hASCs from clinically established hASCs), future
experiments are being conducted to determine if inhibitory effect
is stronger in autologous T cells.
The limitations of the study are evident as this paper has been
purely focused on the in vitro role of exo-hASCs against in vitro
activated T cell subsets, and future experiments should confirm
these observations on in vivo animal models. These in vivo animal
models will help us to define the optimal the route, dosing and
frequencies of exo-hASCs administration.
In summary, this paper provides a better understanding of exo-
hASCs for their future applicability in clinical practice. Moreover,
in terms of immunomodulation, our in vitro results demonstrated
a parallelism between hASCs and exo-hASCs.
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